{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:40:20Z","timestamp":1792442420974,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI23\/00046"],"award-info":[{"award-number":["PI23\/00046"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"DOI":"10.1186\/s41927-026-00694-0","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:33:11Z","timestamp":1789389191000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ultrasensitive serum levels of interleukin 13 in systemic lupus erythematosus patients: a cross-sectional study"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0197-5267","authenticated-orcid":false,"given":"Iv\u00e1n","family":"Ferraz-Amaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0398-9072","authenticated-orcid":false,"given":"Juan Carlos","family":"Quevedo-Abeledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5124-8944","authenticated-orcid":false,"given":"Beatriz","family":"Tejera-Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1026-7318","authenticated-orcid":false,"given":"Enrique","family":"Garc\u00eda-Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9067-3668","authenticated-orcid":false,"given":"Luisa Mar\u00eda","family":"Villar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2245-4639","authenticated-orcid":false,"given":"Javier Gonzalo","family":"Ocejo-Vinyals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6525-2944","authenticated-orcid":false,"given":"Raquel","family":"Largo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7924-7406","authenticated-orcid":false,"given":"Miguel \u00c1ngel","family":"Gonz\u00e1lez-Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"694_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/ANNUREV.IMMUNOL.21.120601.141142","volume":"21","author":"TA Wynn","year":"2003","unstructured":"Wynn TA. IL-13 effector functions. Annu Rev Immunol. 2003;21:425\u201356. https:\/\/doi.org\/10.1146\/ANNUREV.IMMUNOL.21.120601.141142.","journal-title":"Annu Rev Immunol"},{"key":"694_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/FMED.2017.00139","author":"E Doran","year":"2017","unstructured":"Doran E, Cai F, Holweg CTJ, Wong K, Brumm J, Arron JR. Interleukin-13 in Asthma and Other Eosinophilic Disorders. Front Med (Lausanne). 2017. https:\/\/doi.org\/10.3389\/FMED.2017.00139. 4 SEP.","journal-title":"Front Med (Lausanne)"},{"key":"694_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0091-6749(98)70080-6","volume":"102","author":"JE De Vries","year":"1998","unstructured":"De Vries JE. The role of IL-13 and its receptor in allergy and inflammatory responses. J Allergy Clin Immunol. 1998;102:165\u20139. https:\/\/doi.org\/10.1016\/S0091-6749(98)70080-6.","journal-title":"J Allergy Clin Immunol"},{"key":"694_CR4","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S0140-6736(15)00157-9","volume":"386","author":"KF Chung","year":"2015","unstructured":"Chung KF. Targeting the interleukin pathway in the treatment of asthma. Lancet. 2015;386:1086\u201396. https:\/\/doi.org\/10.1016\/S0140-6736(15)00157-9.","journal-title":"Lancet"},{"key":"694_CR5","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1067\/mai.2003.1333","volume":"111","author":"GK Khurana Hershey","year":"2003","unstructured":"Khurana Hershey GK. IL-13 receptors and signaling pathways: An evolving web. J Allergy Clin Immunol. 2003;111:677\u201390. https:\/\/doi.org\/10.1067\/mai.2003.1333.","journal-title":"J Allergy Clin Immunol"},{"key":"694_CR6","doi-asserted-by":"publisher","unstructured":"Gallagher A, Edwards M, Nair P, Drew S, Vyas A, Sharma R, et al. Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma. Cochrane Database Syst Rev. 2021;10. https:\/\/doi.org\/10.1002\/14651858.CD012929.PUB2.","DOI":"10.1002\/14651858.CD012929.PUB2"},{"key":"694_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/J.CYTOGFR.2018.12.001","volume":"45","author":"YM Mao","year":"2019","unstructured":"Mao YM, Zhao CN, Leng J, Leng RX, Ye DQ, Zheng SG, et al. Interleukin-13: A promising therapeutic target for autoimmune disease. Cytokine Growth Factor Rev. 2019;45:9\u201323. https:\/\/doi.org\/10.1016\/J.CYTOGFR.2018.12.001.","journal-title":"Cytokine Growth Factor Rev"},{"key":"694_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3109\/08916930108994122","volume":"34","author":"S Morimoto","year":"2001","unstructured":"Morimoto S, Tokano Y, Kaneko H, Nozawa K, Amano H, Hashimoto H. The increased interleukin-13 in patients with systemic lupus erythematosus: relations to other Th1-, Th2-related cytokines and clinical findings. Autoimmunity. 2001;34:19\u201325. https:\/\/doi.org\/10.3109\/08916930108994122.","journal-title":"Autoimmunity"},{"key":"694_CR9","first-page":"213","volume":"20","author":"A Spadaro","year":"2002","unstructured":"Spadaro A, Rinaldi T, Riccieri V, Taccari E, Valesini G. Interleukin-13 in auto-immune rheumatic diseases: Relationship with the autoantibody profile. Clin Exp Rheumatol. 2002;20:213\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"694_CR10","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1002\/ART.42146","volume":"74","author":"Z Chen","year":"2022","unstructured":"Chen Z, Flores Castro D, Gupta S, Phalke S, Manni M, Rivera-Correa J, et al. Interleukin-13 Receptor \u03b11-Mediated Signaling Regulates Age-Associated\/Autoimmune B Cell Expansion and Lupus Pathogenesis. Arthritis Rheumatol. 2022;74:1544\u201355. https:\/\/doi.org\/10.1002\/ART.42146.","journal-title":"Arthritis Rheumatol"},{"key":"694_CR11","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/1529-0131(199709)40:9<1725::AID-ART29>3.0.CO;2-Y","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725. https:\/\/doi.org\/10.1002\/1529-0131(199709)40:9%3C1725::AID-ART29%3E3.0.CO;2-Y.","journal-title":"Arthritis Rheum"},{"key":"694_CR12","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman DD, Iba\u00f1ez D, Urowltz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288\u201391.","journal-title":"J Rheumatol"},{"key":"694_CR13","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/art.1780390303","volume":"39","author":"D Gladman","year":"1996","unstructured":"Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363\u20139. https:\/\/doi.org\/10.1002\/art.1780390303.","journal-title":"Arthritis Rheum"},{"key":"694_CR14","unstructured":"Mosca M, Bombardieri S. Assessing remission in systemic lupus erythematosus. Clin Exp Rheumatol 2006;24(6 Suppl 43):S\u201399\u2013104."},{"key":"694_CR15","doi-asserted-by":"publisher","unstructured":"van Vollenhoven RF, Bertsias G, Doria A, Isenberg D, Morand E, Petri MA, et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med. 2021;8. https:\/\/doi.org\/10.1136\/LUPUS-2021-000538.","DOI":"10.1136\/LUPUS-2021-000538"},{"key":"694_CR16","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/ACR.23109","volume":"69","author":"A Polachek","year":"2017","unstructured":"Polachek A, Gladman DD, Su J, Urowitz MB. Defining Low Disease Activity in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2017;69:997\u20131003. https:\/\/doi.org\/10.1002\/ACR.23109.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"694_CR17","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","volume":"27","author":"TM Wallace","year":"2004","unstructured":"Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487\u201395.","journal-title":"Diabetes Care"},{"key":"694_CR18","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/JAMA.285.19.2486","volume":"285","author":"Expert Panel on Detection E and T of HBC in AEP on DE","year":"2001","unstructured":"Expert Panel on Detection E and T of HBC in AEP on DE. T of HBC in A. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486\u201397. https:\/\/doi.org\/10.1001\/JAMA.285.19.2486.","journal-title":"JAMA"},{"key":"694_CR19","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1093\/EURHEARTJ\/EHAB309","volume":"42","author":"SCORE2 risk prediction algorithms","year":"2021","unstructured":"SCORE2 risk prediction algorithms. : new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42:2439\u201354. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAB309.","journal-title":"Eur Heart J"},{"key":"694_CR20","doi-asserted-by":"publisher","unstructured":"Canales RA, Wilson AM, Pearce-Walker JI, Verhougstraete MP, Reynolds KA. Methods for handling left-censored data in quantitative microbial risk assessment. Appl Environ Microbiol. 2018;84. https:\/\/doi.org\/10.1128\/AEM.01203-18. ;WGROUP:STRING:PUBLICATION.","DOI":"10.1128\/AEM.01203-18"},{"key":"694_CR21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1159\/000343145","volume":"34","author":"PJ Touboul","year":"2012","unstructured":"Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al. Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis. 2012;34:290\u20136. https:\/\/doi.org\/10.1159\/000343145.","journal-title":"Cerebrovasc Dis"},{"key":"694_CR22","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1093\/EURHEARTJ\/EHL254","volume":"27","author":"S Laurent","year":"2006","unstructured":"Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:2588\u2013605. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHL254.","journal-title":"Eur Heart J"},{"key":"694_CR23","doi-asserted-by":"publisher","unstructured":"Klabusay M, Kohutova V, Coupek P, Nenickova M, Tesarova E. Simultaneous analysis of cytokines and co-stimulatory molecules concentrations by ELISA technique and of probabilities of measurable concentrations of interleukins IL-2, IL-4, IL-5, IL-6,CXCL8 (IL-8), IL-10, IL-13 occurring in plasma of healthy blood do\u2026. Mediators Inflamm. 2006;2006. https:\/\/doi.org\/10.1155\/MI\/2006\/65237.","DOI":"10.1155\/MI\/2006\/65237"},{"key":"694_CR24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1155\/2013\/290670","volume":"35","author":"J Doucet","year":"2013","unstructured":"Doucet J, Zhao A, Fu J, Avrameas A. Development and validation of an ELISA at acidic pH for the quantitative determination of IL-13 in human plasma and serum. Dis Markers. 2013;35:465\u201374. https:\/\/doi.org\/10.1155\/2013\/290670.","journal-title":"Dis Markers"},{"key":"694_CR25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jim.2009.08.012","volume":"350","author":"SLK Agee","year":"2009","unstructured":"Agee SLK, Kasaian SJ, Forlow MT, Durn SB, Minyard BL. Analytical validation of a highly sensitive microparticle-based immunoassay for the quantitation of IL-13 in human serum using the Erenna\u00ae immunoassay system. J Immunol Methods. 2009;350:161\u201370. https:\/\/doi.org\/10.1016\/j.jim.2009.08.012.","journal-title":"J Immunol Methods"},{"key":"694_CR26","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jim.2015.08.006","volume":"426","author":"B Gaye","year":"2015","unstructured":"Gaye B, Sikkema D, Lee TN. Development of an ultra-sensitive single molecule counting assay for the detection of interleukin-13 as a marker for asthmatic severity. J Immunol Methods. 2015;426:82\u20135. https:\/\/doi.org\/10.1016\/j.jim.2015.08.006.","journal-title":"J Immunol Methods"},{"key":"694_CR27","doi-asserted-by":"publisher","first-page":"931018","DOI":"10.1155\/2010\/931018","volume":"2010","author":"Q Lu","year":"2010","unstructured":"Lu Q, Zhao M, Tang J, Gao F, Wu X, Liang Y, et al. Hypomethylation of IL10 and IL13 Promoters in CD4\u2009+\u2009T Cells of Patients with Systemic Lupus Erythematosus. Biomed Res Int. 2010;2010:931018. https:\/\/doi.org\/10.1155\/2010\/931018.","journal-title":"Biomed Res Int"},{"key":"694_CR28","doi-asserted-by":"publisher","unstructured":"Selvaraja M, Abdullah M, Arip M, Chin VK, Shah A, Nordin SA. Elevated interleukin-25 and its association to Th2 cytokines in systemic lupus erythematosus with lupus nephritis. PLoS ONE. 2019;14. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0224707.","DOI":"10.1371\/JOURNAL.PONE.0224707"},{"key":"694_CR29","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/ki.2015.196","volume":"88","author":"K Renner","year":"2015","unstructured":"Renner K, Hermann FJ, Schmidbauer K, Talke Y, Rodriguez Gomez M, Schiechl G, et al. IL-3 contributes to development of lupus nephritis in MRL\/lpr mice. Kidney Int. 2015;88:1088\u201398. https:\/\/doi.org\/10.1038\/ki.2015.196.","journal-title":"Kidney Int"},{"key":"694_CR30","doi-asserted-by":"publisher","first-page":"7209872","DOI":"10.1155\/2018\/7209872","volume":"2018","author":"CP Mart\u00ednez-Reyes","year":"2018","unstructured":"Mart\u00ednez-Reyes CP, G\u00f3mez-Arauz AY, Torres-Castro I, Manjarrez-Reyna AN, Palomera LF, Olivos-Garc\u00eda A, et al. Serum Levels of Interleukin-13 Increase in Subjects with Insulin Resistance but Do Not Correlate with Markers of Low-Grade Systemic Inflammation. J Diabetes Res. 2018;2018:7209872. https:\/\/doi.org\/10.1155\/2018\/7209872.","journal-title":"J Diabetes Res"},{"key":"694_CR31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1042\/CS20190961","volume":"134","author":"LD Low","year":"2020","unstructured":"Low LD, Lu L, Chan CY, Chen J, Yang HH, Yu H, et al. IL-13-driven alterations in hepatic cholesterol handling contributes to hypercholesterolemia in a rat model of minimal change disease. Clin Sci (Lond). 2020;134:225\u201337. https:\/\/doi.org\/10.1042\/CS20190961.","journal-title":"Clin Sci (Lond)"},{"key":"694_CR32","doi-asserted-by":"publisher","first-page":"5351","DOI":"10.1111\/JCMM.16566","volume":"25","author":"N Qian","year":"2021","unstructured":"Qian N, Gao Y, Wang J, Wang Y. Emerging role of interleukin-13 in cardiovascular diseases: A ray of hope. J Cell Mol Med. 2021;25:5351\u20137. https:\/\/doi.org\/10.1111\/JCMM.16566.","journal-title":"J Cell Mol Med"},{"key":"694_CR33","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/EMMM.201201374","volume":"4","author":"L Cardilo-Reis","year":"2012","unstructured":"Cardilo-Reis L, Gruber S, Schreier SM, Drechsler M, Papac-Milicevic N, Weber C, et al. Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype. EMBO Mol Med. 2012;4:1072\u201386. https:\/\/doi.org\/10.1002\/EMMM.201201374.","journal-title":"EMBO Mol Med"},{"key":"694_CR34","doi-asserted-by":"publisher","unstructured":"Svensson C, Eriksson P, Bjarneg\u00e5rd N, Jonasson H, Str\u00f6mberg T, Sj\u00f6wall C, et al. Impaired Microcirculation and Vascular Hemodynamics in Relation to Macrocirculation in Patients With Systemic Lupus Erythematosus. Front Med (Lausanne). 2021;8. https:\/\/doi.org\/10.3389\/FMED.2021.722758.","DOI":"10.3389\/FMED.2021.722758"},{"key":"694_CR35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1084\/JEM.180.1.75","volume":"180","author":"SEW Jacobsen","year":"1994","unstructured":"Jacobsen SEW, Okkenhaug C, Veiby OP, Caput D, Ferrara P, Minty A. Interleukin 13: novel role in direct regulation of proliferation and differentiation of primitive hematopoietic progenitor cells. J Exp Med. 1994;180:75\u201382. https:\/\/doi.org\/10.1084\/JEM.180.1.75.","journal-title":"J Exp Med"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-026-00694-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-026-00694-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-026-00694-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:02:29Z","timestamp":1792440149000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-026-00694-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["694"],"URL":"https:\/\/doi.org\/10.1186\/s41927-026-00694-0","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"23 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted at four tertiary hospitals in Spain: Hospital Universitario de Canarias (Approval Number CHUC-2023-48), Hospital Universitario Doctor Negr\u00edn (Approval Number 2021-023-1), Hospital Insular de Gran Canaria (Approval Number 2021-023-1), and Hospital Fundaci\u00f3n Jim\u00e9nez D\u00edaz (Approval Number PIC135-23). The study protocol received approval from the Institutional Review Committees of all participating hospitals, and all participants provided written informed consent.Research was conducted in accordance with relevant guidelines and the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no conflicts of interest. Nevertheless, I.F.-A. would like to acknowledge that he has received grants\/research supports from Abbott, MSD, Janssen, and Roche, as well as consultation fees from company sponsored speakers\u2019 bureaus associated with Abbott, Pfizer, Roche, Sanofi, Celgene, and MSD. Prof. M.A.G-G. has received research supports from GSK and Otsuka as well as consultation fees\/participation from company sponsored speakers\u2019 bureaus associated to GSK.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"80"}}